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I cannot tell you what a thrill it was for me to be in here 
and an honor (at the Pairs Annual Scientific Meeting 2017). 
As someone who has been a passionate about education and 
spreading the words so to speak regarding Interventional 
Radiology and less invasive therapy, in general, it is really 
exciting to see what it is going on in this region, having 
sat through lectures yesterday and today again. Everyone 
here should be really proud of what is happening right 
here in this region. For me, as an educator and someone 
who has tried to take the message of those early years and 
spread it worldwide, it is a lot of personal satisfaction, so 
congratulations. 
I was given this title in talking about the future, I will 
shorten it a little bit regarding "ascending" and in many 
ways, Interventional Radiology, to many people, it's already 
arrived, it's already gotten there already. However, actually 
to me, it has always been about the future and about where 
our platforms can take us and where we are going. People 
who work close to me know I live in a window that is about 
5 years down the line. It is frustrating to people who are close 
to me because sometimes I do not pay attention enough to the 
present, and so I am going to try to give a little insight in some 
of the big pictures, and there were so many great lectures that 
have occurred already in dealing with new technologies and 
new approaches to critical limb ischemia (CLI), peripheral 
artery disease, and aortoiliac disease. I am not going to dwell 
so much on that but try and give you a big picture. 
At this year's SIR meeting, there was an interesting talk 
given by my Mike Darcy, who is the Dotter Lecturer 
this year. As he is talking to his fellows, he gave his 
fellows a quiz with some of the big names so to speak of 
Interventional Radiology, mixed in with names of famous 
performers, artists, musicians, or whatever that was, so 
there was Cesare Gianturco and there was a Cesar Romero, 
and they had to pick which one is an interventional 
radiologist and are they dead or alive and what did they do. 
He showed this as part of the Dotter Lecture. I was pretty 
pleased to see there were three interventional radiologists 
that all of them recognized. I was only recognized by 90% 
of the fellows, but the good news is they thought everyone 
else is dead, including Ernest Ring, but at least 90% 
thought I was alive, so it was good. 
In my perspective, I want to change my presentation 
today a little to talk a little bit about the past so that you 
would understand not only some of greats and how we 
got to where we are but also how important step-by-step 
technology is and every incremental step we make is an 
opportunity for the future. It is only one step moving on 
with to the future. 
Hence, in talking about this subject, I think it is important 
to understand what IR is and I spent a good part of my 
career trying to change my identification because, in my 
institution, I actually lead the cardiac surgery program 
and the interventional cardiology program. We integrated 
all services up to a final encounter pathway, but I found 
it actually to be unsuccessful and today I think we are 
interventional radiologists and so it is best if we train that 
way and we, of course, do image-guided procedures that are 
therapeutic in nature, but importantly, we provide clinical 
care to patients. This is probably the most important thing 
we do, and we do it across diverse group of procedures, 
which differentiates us from many in Medicine. 
We are a discipline that is spread throughout the world, as 
you see here in this meeting, offering patients less invasive 
solutions to significant medical problems, and we are all 
about innovation and change to health care, and that is one 
of the things that are different between us and traditional 
vascular surgeon, traditional endoscopies, or traditional 
anyone that is involved in less invasive therapy. Most 
interventional radiologists at their core are looking forward 
to change in innovation. 
Hence, I think our specialty is generally considered and 
has been worn when Charles Dotter, not just did the first 
angioplasty that was obviously a very significant event, but 
more importantly when he published this first paper and he 
talked about two important things; one is using the catheter 
as a surgical instrument and so most of us in Intervention 
Radiology are, in fact, surgeons. Many of my fellows call 
themselves minimally invasive surgeons or endovascular 
surgeons in the United States, but importantly from this 
little experience, he thought enough to forget all of the 
things that you see here in this slide and virtually all of 
which has become true. 
Hence, if we look at the impact that Interventional 
Radiology has had on Medicine, our general space. 
Virtually everything on this list has been totally changed 
by Interventional Radiology. Some surgery has been 
totally eliminated. When I was a radiology resident, the 
most common surgical procedure in the United States 
was exploratory laparotomy. It is pretty amazing when 
you think about it and today, you know, it is unheard of, 
we can figure everything out with image-guided biopsies 
and sophisticated imaging, feeding problems, peripheral 
pulmonary AVMS, uterine fibroids, colonic bleeding, 
subarachnoid hemorrhage, and coronary artery disease. 
All these are the things that we have had a very dramatic 
impact on and, in fact, Vascular and Interventional 
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Radiology propelled this entire movement in Medicine 
toward less invasive therapies whether it be laparoscopic, 
endoscopic, or neurovascular, and many of the people 
that came from our early circles in the industry are the 
ones that founded these various companies to go out 
and create laparoscopic approaches, endo any kind of 
approaches. 
Hence, we have developed as a specialty over the past 
40 years, and in the United States 3 years ago, achieved 
subspecialty status, actually specialty status, with 
accreditation by the American Board of Medical Specialist. 
This has been a scary thing, I note to many of my 
colleagues in Europe, who maybe do not agree with this 
direction but that is the direction that we, in the United 
States, feel really important to define what IR is. Vascular 
therapy has been a cornerstone of intervention, but in many 
ways, it was just a platform for us to spread out and use 
these techniques and other types of applications. When I 
started, virtually all cardiac catheterization was done by 
radiologist and so, one of the reasons I am particularly in a 
place where I am leading the cardiovascular program as I 
was old enough to basically have cardiovascular experience 
that most radiologists do not today, but that transitioned 
of course, and once balloon angioplasty developed, our 
cardiology colleagues became much more interested in this 
space. 
Hence, if we look back in the earlier years of intervention 
when the term Interventional Radiology began to develop, 
you can look at kind of the procedures that were the "bread 
and butter" of procedures, and this is what everybody's 
workday looks like. However, things have really 
dramatically changed and one of the things I think all of us 
understand is that, the procedures that we do today, most 
that are important, most of them did not exist 10 years 
ago or 12 years ago, you pick the time and so, the nature 
of Interventional Radiology, from an educational point 
of view, is we have to train our fellows to do procedures 
that do not exist. This is to give them the skills, to give 
ourselves the skills, and the mental strength to be able to 
do things that do not exist because that is our nature. 
These are some early papers. You can see in 1979, we were 
publishing early balloon angioplasty, I thought I would 
share some of these with you for historic purposes in 
hypertension in 1979. 
Right from the beginning, myself and you will see 
Dr. Dake's name, there who was a partner of mine, early 
in his career, began to understand that we had to take 
this evolving specialty and become significant, not just 
be a practitioner; and to be significant, we had to become 
a clinical discipline. It was pretty obvious that we were 
the only people in Medicine who were not taking care of 
our patients. Everybody else is taking care of the patients 
that they did procedures on, and coming from a clinical 
background myself, it just really did not make any sense. 
Hence, we began to write along with others about the 
importance of clinical training. 
Finally in the United States, we see this actually being 
formally structured as the US training pathways are 
changing. As you know, there is going to be a residency 
in Interventional Radiology now, meaning the fellowship 
are going to go away, and these residencies are going to 
include time in critical care, time on the floors, and clinical 
management, and refreshing the skills or adding to the 
skills that we need. 
Today, in modern IR, hospitals at least in the United States 
cannot function without an interventional radiologist or 
more, and there are hospitals that have lost their IRs over 
turf battles and things like that, and they have been written 
up in journals and created emergencies for patient care. It 
is really pretty amazing how we are woven into the metric 
of day-to-day practice. 
Again, Interventional Radiology has accomplished so 
much. If you were to look at the curriculum vitae of our 
specialty and what we have accomplished whether it is in 
peripheral arterial disease, cancer treatment, palliative care, 
and treatment of aneurysms. However, things have changed 
over the past 20 years, and what we have found is that we 
have developed and we practised procedures that other 
people want to do and the people who want to do them 
are the disease management doctors. They are, you know, 
somebody who was trained on how to take care of vascular 
disease and want to be able to do the procedures associated 
with taking care of his or her patients and so this has been 
a challenge for our discipline. We have been able to figure 
it out in Miami and survived in a significant way. 
It has been a challenge to IR as we have been unable, in 
many cases, to hold on to our innervations. 
Hence, I just want to talk a little bit about some megatrends 
and challenges. Now, instead of being a developing field, 
endovascular therapy is really a mature field. It is very 
broad. It is very important for us to define who benefits 
and bring science to this discipline. Some of them were 
cardiology and vascular surgery. 
One of the other megatrends has been the effect of 
computed tomography angiography and magnetic resonance 
angiography, so our trainees no longer have diagnostic 
angiography to use as a platform for developing basic 
catheter skills. They are expected just as surgeons to go 
from zero into doing some sort of complex recanalization; 
it is pretty challenging from a training and educational 
point of view. We obviously are defining now the role 
and methods of drug delivery, and we are experiencing a 
worldwide in epidemic CLI. 
Hence, it is uncommon in us, especially in these regions and 
other regions of the world, to make endovascular therapy 
more cost-effective and less expensive both, and how are we 
going to do this. I am going to talk more about amputation 
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rates and some of the public health issues, but more and 
more, Interventional Radiology is challenged now to produce 
proof of our procedures. When we did the first angioplasty, 
it was pretty intuitive, "Wow! This patient can walk now 
and did not need surgery." Well, that no longer gets us 
anywhere and the compelling need for data in clinical trials 
is important and you will hear that I talk about our failures 
and some of the new procedures that you will see here are 
going to need data and proof before our colleagues accept it. 
We look at endovascular as very broad, so to me treatment 
of an AVM is endovascular, pretty much anything if we 
take the number 2 broad definition and how we, ourselves, 
are organized, and it is any discipline, any organ system, 
anything that involves image-guided therapy. However, 
others can look at it in a different way, they can look at it, 
to many vascular surgeons, endovascular means aortic work 
and somehow peripheral intervention means something 
different. Hence, we still have a lot of definitional issues 
within the entire space. 
If we look at IR today, specifically endovascular therapy 
has replaced much traditional vascular surgery, but it 
has also become cardiovascular surgery. In the United 
States, about 30 percent of this is done by interventional 
radiologist and has become a multidisciplinary field. That 
is just the way it is, it is steady but it is multidisciplinary, 
and so interventional radiologists, among other things, 
needs to learn how to compete. 
With endovascular therapy, we can do a lot of things, 
opening vessels, closing vessels, and treating cancer; it is 
all part of using the circulation as a therapeutic conduit 
The pioneers in this space really started in the 60's; these 
are Stanley Baum and Josef Rosch, who unfortunately 
both passed away and the concept of using the catheter for 
surgical tool, in this case to deliver drugs, was developed 
by them. The concept of trying to get a balloon to make an 
artery bigger than the catheter itself is generally credited to 
Werner Porstmann who, at that time, was behind the iron 
curtain in Charite Hospital in East Berlin, and I thought I 
would share this with you, this is actually the first patient 
I treated in Rome; it was in 1974, and I am the one with 
the beard and the big hair along with the others, but this 
patient did incredibly well with that corset catheter for 6 or 
7 years we had angios on this patient, it was amazing what 
could be done and this is what fired our whole discipline, 
followed by Gruentzig who developed the technology to 
reach his dream of treating coronary arteries, and along the 
way, incorporated the vascular system as well, and then, a 
group of people took the next step which was opposed by 
Dotter actually of managing thrombus and managing the 
clot with a catheter and then stents came along, and the 
thing about these and the reason that I am going through 
this is that each of these was one step going to the next. 
Hence, stents were interesting as you can see, but maybe 
there were more important to develop a platform for  
endografts and the concepts of endografts or the concept of 
drug delivery. Much more important, drug delivery or the 
stent and so each of these incremental concepts were very 
important in moving our field forward. 
Now, we still have a ways ago, people are dying of 
aneurysms. These are some of the well-known people that 
have passed away from ruptured aneurysms. Some of them 
knew they had aneurysm, some of them did not and we 
know that aneurysms can occur everywhere, and of them 
we knew had them some of them we did not, we know that 
we have made a great stride here but also we have taken 
something that was an idea and made it standard of care. 
And so, each of these areas that we have touched on, we 
have actually made standard of care and each and every 
one of you are part of a field that should take great pride in 
that. It has not all been perfect and one of the things you 
have to know about innovation is that innovation involves 
failure, and these are some of the devices that have failed. 
Some types they fail early, some types they fail late, but 
we have to be careful when we talk to our patients, in 
particular, to be intellectually honest about what we know 
and what we do not know and some of the devices, I am not 
sure if some others which have failed. However, where are 
we trying to take endovascular aneurysm repair (EVAR)? 
The fact that we can treat an aneurysm less invasively, that 
is not the end-game; that is the beginning. The end-game is 
for patients to be able to come in, have their aneurysm fixed 
and go home the same day. That is dramatically changing 
in the way healthcare is delivering. We have been very 
interested in this for a long time, and it is not just going to 
involve the technology or the right piece of equipment, it is 
going to involve a total change in how we manage patients 
and how we get paid for patients. In the United States for 
instance, if you were to treat a patient as an outpatient, you 
cannot get paid; it is required to be an inpatient, as a result, 
this particular study, the LIFE study was done on inpatients 
that simulated outpatients, and they all had percutaneous 
access, no general anesthesia, no ICU and were pushed for 
next-day discharge with 250 patients and this was recently 
presented at ISET and has been presented in other meetings 
as well, and you can see that comparing it to that analysis 
as traditional EVAR, that there was great safety, reduced 
procedure time. The length-of-stay was 1.2 days because 
we were not allowed to send them home basically during 
the course of this trial, and importantly, the readmission rate 
was much, much lower at 30 days than traditional EVAR 
patients, so there was no intent to push these patients out 
only to have them be readmitted in a short period. 
Here, you can see the performance goal in terms of major 
adverse event (MAE) rates, and you can see that of the 
250 patients in a so-called fast track, there was only one that 
had any type of MAE and that was a readmission in 30 days. 
Along the way, you are going to hear more about during 
this meeting. As image-guided therapist, imaging has been 
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of significant improvement to us as we can combine what 
used to be just looking at a flat screen like this and learning 
how to do this in our heads to be being able to superimpose 
3D models, and this is not just for the uneducated or 
people that are not radiologists. This technology is making 
all of us better by able to see precisely and understand 
what we are doing and nowadays with image fusion, we 
can actually move the table and around rotate and keep 
everything synced up and so for doing very complex cases, 
it has really been a significant improvement. 
One of the important areas of Interventional Radiology 
that is becoming more important is the issue of CLI, and 
there were a lot of talks yesterday, great talks about how 
to treat CLI but I am not going to talk about that. What I 
want to talk about is CLI as a disease and point out that 
25% of our patients with CLI are going to be dead in 
12 months, probably 70% are going to be dead in 3 years 
and so similar to what we did when we started treating 
SFA disease, it is really important that if you are thinking 
about developing a CLI program, that you start thinking 
about the patient as a whole, not just of the wound and 
yesterday, we saw some cases where revascularization 
was made but the patient lost their leg because of lack of 
teamwork and lack of combined therapy that is necessary. 
Hence, we know that is an epidemic and pandemic and 
we think that there is a great opportunity from the public 
health point of view. 
Now, all ideas are not just technology. We have some great 
thinkers in our space, one of them being Dr. Manzi, who is 
on the program this year who thought about approaching 
things on these very tiny arteries in the foot that most 
of us thought were impossible. In fact, I heard someone 
yesterday during the comment section, and the idea of 
combining retrograde and antegrade access to accomplish 
something which could have been a failure before or to 
avoid failure is an example of how creative interventional 
radiologists are in creating unique solutions. 
In this particular case, I think by now probably all of you 
had experienced here, you can act up immediately and it is 
very helpful in this particular case, myself and my vascular 
surgical colleagues are working together, and teamwork is 
very important to get greater results here. 
Hence, all ideas and not technology or many of them, 
especially in CLI, come from our brains without a lot of 
expensive thought or technology. Hence, what is CLI? Well, 
we did a survey in the United States and if you survey 10 
people what CLI is, you get 10 different answers, and what 
that means in the United States at least is that we cannot 
get paid for it. Hence, if a patient comes in with CLI and 
we are trying to figure out how much does it cost to take 
care of a patient with CLI, it is very, very difficult because 
there are no codes, there is no identification, and we are 
very interested in developing a CLI program to prolong life 
and reduce amputations. 
So for instance, if you were to look a Rutheford 6, these 
are three different feet. They certainly do not have the same 
probability of success in terms of saving that foot and yet, 
right now, we do not have any way of really classifying 
those differences, and so there is really a critical need to 
do that. 
Recently, in the United States, the Society of Vascular 
Surgery has proposed the W1FI system, which would allow 
us to be able to differentiate what the classifications are. 
What we know is that 50% of the patients that actually 
get revascularization, 25% are going to be dead in a year, 
30% are still going to have amputations of some sort, and 
only 25% are going to have their CLI resolved. Hence, 
interventional radiologists want to look for opportunity. We 
generally want to create procedures and technologies that 
fill gaps but to do that for CLI, we need to develop metrics 
for success, and we need a definition of patient population. 
If you compare us to ST-segment elevation myocardial 
infarction, for instance, in acute myocardial infarction, 
we are so far off of the metrics necessary to really make 
an impact on CLI and that there is a lot of work to do. 
And so, this year at ISET, myself and a number of others 
announced the formation of the CLI Global Society. Those 
of you who are involved in this hopefully will get involved 
in this phase, but this is not a society that has meetings and 
things like that. The mission is to improve the quality of 
life by preventing amputations and death due to CLI, so we 
actually want to take that mortality rate and lower it. We 
want to take amputation rates country by country and lower 
it, similar to what the American Heart Association has been 
doing for cardiac mortality. 
The next technology I want to briefly talk about are things 
that are going to be important. We know about drug-eluting 
balloons and drug-eluting stents, but Bioabsorbable 
Scaffolds are the next hot thing, leaving nothing behind 
and a lot of people believe this is the next great thing. 
However, in the past year, it has become clear that there 
are significant issues related with this technology that is 
probably going to bring some caution. One is that generally, 
they require OCT to be able to determine whether you got 
good wall apposition. Most interventional radiologists do 
not have OCT as an integral part of the laboratory. That 
also means slow cessation to be able to image it. However, 
the imaging is exquisite of course. I think it is certainly 
true that device-drug combinations are ultimately going to 
be part of what we treat all patients with, in my opinion, 
but I think regarding Bioabsorbable, all we can say is that 
they may play a role today but they are not the answer yet. 
Now, I mentioned also that in pushing for change and 
pushing for innovation, we have made some mistakes 
and we have some procedures that have failed and they 
have had an impact on failure and this year at SIR, two 
important trials were released. One is the kr fRACT trial 
which is a randomized trial of iliofemoral thrombolysis. 
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There are a lot of problems with this trial by the way, but 
the end-point was venous stasis syndrome and it turned out 
to be no difference at 2 years. Morever, the other one was 
on multiple sclerosis. 
How many people remember what the frenzy was like 
5 years ago with centers opening up, many of them in this 
region to treat these patients, and now what is happening is 
too many interventional radiologists were really unfortunate 
carrying the flag on this. Most of us were skeptical but 
others were not, and a lot of patients got procedures they 
did not need as a result. 
Renal denervation is another example. Multibillion dollars 
spent on technology and then a single trial which was 
misinterpreted, in my opinion, more or less killed an entire 
space of research which continues on. 
Hence, how about isolated organ perfusion? Anybody 
involved with that? I think there were some in this region 
that were great promise, probably the wrong drug, the 
wrong cancer, and it wound up being a failure. So as IRs 
matured, we know that there have been some failures that 
we have had and we have to be prepared for that. 
Now, what final thing I want to mention is what about 
threats to us. Well, we may not have heard about Tom 
Lawson, he is a scientist. He used to be at Duke University, 
but I think he left to join this company. However, he 
basically figured out how to manufacture artificial blood 
vessels, and they are actually being put in patients in 
Eastern Europe now. 
Now, if you can make a blood vessel and you can deliver 
drug out of that blood vessel, you know, then think about 
that as it relates to stents and the things we do. This could 
be a potential game-changer for all of us. 
Robotics, I think you all know what happened to robotics. 
Unfortunately, myself and Professor Hamady, we believe 
that there is a future there but I am not going to dwell on 
it because of recent events, but we do believe that there is 
an opportunity. 
And then finally, I think, on a positive note, what are the 
next great areas that we are going to be involved in and 
one of the big emphases is now on pulmonary embolism. 
It is a very common cause of death in hospitalized patients, 
and there is big initiative that is welled up now to look 
at submassive and massive pulmonary embolism and the 
role of interventional therapy. These are very dramatic 
things. In this particular patient, a catheter was put in the 
main pulmonary artery, just maceration by spinning the 
catheter followed by catheter-directed lysis in this case 
with ultrasound enhancement and you can see the images 
on the lower right. But most importantly, if you look at the 
right ventricle-to-left ventricle ratio before and after, you 
can see that this has had very significant effect on cardiac 
function. The reason that patients with PE die is because  
of acute right heart failure generally. They die reflexively 
and deal of acute right heart failure. Hence, these are 
potential life-threatening initiatives, and the development 
of pulmonary embolism response teams is a big initiative. 
There are some other out-of-box applications I think you 
are aware of, prostatic embolization. People are very, very 
excited about that. We can see the prostate shrink. How 
could this possibly not work? How could CCSVI not 
work? How could any of these other things not work? We 
need clinical data and we need trials and those of us in the 
space should be demanding it, same thing with left gastric 
embolization for morbid obesity. Very exciting! 
Then, finally, Interventional Oncology this is the great 
savior of Interventional Radiology. I gave a talk at a 
guest meeting 2 years ago on the death of Interventional 
Oncology, so the same thing can happen if we do not 
embrace clinical management of patients. Hence, if you 
look at this, this is clinical Interventional Radiology, 
technology, and multidisciplinary care has to interact. 
Hence those of you, who are engaged in this space, need 
to be able to be prepared to learn a lot about cancer, a 
lot about longitudinal management. This is not just about 
picking the right way to kill a cancer focally but managing 
the morbidity long term as a result of that. When you 
start giving radiotherapy in any type of way, you need to 
be prepared to manage those patients longitudinally and 
prospectively in terms of providing input on patient safety 
and long-term morbidity. 
We know that our space is seeing a lot of imaging, you can 
hear more a about that, and the final thing that I want to 
share with you is this idea: 
What if you can put in stent in someone and when that 
stent starts narrowing, you get a warning on your iPhone 
or in your office that that stent is starting to fail. Well, this 
is the technology we are beginning to look at in the case 
of both bypass grafts in this model for dialysis fistulas. 
This was also presented at ISET that first-in-man trials 
are getting ready to be run. But you can see, here is the 
input on animals who had dialysis grafts put it and then 
a stenosis was created, you can see the follow-up on the 
image on your lower image. 
While for most of us interested in bypass graft is less, they 
can manufacture and put this piezoelectric sensor actually 
into a multisegmented stent which, in theory, could provide 
us feedback and reduce the need for a lot of other studies 
and then send the signal back to an iPhone. 
So what about the future? Well, for those of you living 
and working in this region, I tried to get some specific 
information, and this is a transient forecast on the business 
side of things and will forecast out through 2024. 
In the inner core, there is the Middle East and Africa, the 
smaller one, which I think is actually an underestimation 
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but you can see the relative growth in different regions 
of the country but I think this is a global mix of different 
types of cases and given our impact on medicine, I see no 
way that it is not going to grow significant in this region. 
If you look at this business analysis in terms of where 
that growth is going to occur, a lot of us projected in still 
in arterial lower extremity revascularization, it is the big 
bubble just above coronary there, in this region as well, as 
well as venous intervention and then, there are some other 
AAA recurrence so on by the smaller bubbles. 
Hence, think about it, how many procedures do you do 
today that you did 10-15 years ago? Probably, a lot but 
you did not do, most of them are new. What are you going 
to be doing 10 years from now? Likely, new procedures 
that are being developed and I would mention a little bit, 
but are being proven today and one of the things you need 
to worry about is creating the environment to do these 
procedures better and especially here in an environment 
where things are very cost sensitive and we rely on 
expensive technology. Hence, we need to work together 
with our industry partners to figure out all the solutions to 
provide such valuable care to patients that you take care 
of or patients that you need without unlimited capital. You 
know, it is definitely a challenge because we have a better 
way to take care of patients than the status quo. 
Hence, I say, continued growth worldwide driven 
by technology and ideas that are going to continue 
innovation, Interventional Radiology is going to begin 
to prove cost efficacy. In the United States even, we are 
on a huge pressure to every clinical trial we do, has to 
have a health-care economics model to it and the FDA is 
starting to require cost-benefit not just a clinical benefit. As 
technology gets more broadly adaptive, cost will decrease 
but also competition is going to increase and training of 
the next generation interventional radiologist will continue 
to be difficult because of the change in procedural mix that 
we are constantly facing. 
Hence, in conclusion, we are very excited to be part of a 
growing specialty of medicine which impacts virtually every 
disease process wherever you live. There is some disease 
that is going on that we can help. It is interesting that it is 
junction between technology and disease as where we sit led 
by physicians who are interested in changing that status quo, 
not simply diagnosing and treating disease. As we grow as 
a specialty, filling more clinical services will be expected by 
others, they are going to expect us to care of these patients and 
remain necessary to compete as well with disease management 
specialists who are interested in doing the same procedures. 
Hence, with that, I thank you very much for your attention. 
I hope some of you might be able to come and visit us next 
year in Miami or South Florida and thank you very, very 
much for your attention. 
Barry T Katzen 
FIU Herbert Wertheim College of Medicine, Miami Cardiac and 
Vascular Institute, Baptist Hospital of Miami, Miami, FL 33176, USA. 
E-mail: Btkatzen@aoLcom 
This is an open access article distributed under the terms of the Creative Commons 
Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, 
and build upon the work non-commercially, as long as the author is credited and the new 
creations are licensed under the identical terms. 
How to cite this article: Katzen BT. The future of IR: Ascending! Keynote 
lecture at the Pairs Annual Scientific Meeting 2017, Dubai, UAE. Arab J 
Intervent Radio! 2017;1:43-8. 
48 The Arab Journal of Interventional Radiology I Volume 1 I Issue 2 July-December 2017 
